



## Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

March 6, 2024

BALA CYNWYD, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in 1x1 investor meetings at the Leerink Partners Global Biopharma Conference, taking place in Miami Beach, FL from March 11 – 13, 2024.

Details on the presentation can be found below.

Date: Wednesday, March 13, 2024

Time: 10 AM ET

Webcast Link: <https://wsw.com/webcast/leerink33/lrmr/2241008>

Following the conclusion of the presentation, a replay will be available for 30 days on the "[Events and Presentations](#)" page of Larimar's website.

### About Larimar Therapeutics

Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar's lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: <https://larimartx.com>.

### Investor Contact:

Joyce Allaire

LifeSci Advisors

[jallaire@lifesciadvisors.com](mailto:jallaire@lifesciadvisors.com)

(212) 915-2569

### Company Contact:

Michael Celano

Chief Financial Officer

[mcelano@larimartx.com](mailto:mcelano@larimartx.com)

(484) 414-2715



Source: Larimar Therapeutics